Robin Washington still is learning.
Attribute part of that to her mid-career switch from tech to biotech, where Gilead Sciences Inc.’s chief financial officer has tackled a new science-heavy vocabulary to see beyond the on-paper numbers. But, really, it’s just the way Washington rolls.
“If you’re truly a business partner, you have to do that,” the 48-year-old Michigan native said. “When I talk to investors, they want numbers, but they also want to know what are the drivers of the future.”